[Long-term effect of amiodarone therapy following myocardial infarct in patients with complex ventricular arrhythmias].
In the BASIS study, an improvement in 1 year survival of patients with asymptomatic complex ventricular arrhythmias with low-dose amiodarone was shown in comparison with an untreated control group. To assess whether this beneficial effect would last for a longer follow-up despite discontinuation of amiodarone therapy after one year, we assessed long-term survival and mode of death in the 91 survivors of the first year in the amiodarone treatment group and the 99 survivors in the control group by phone calls to private physicians, patients and hospitals. During a median follow-up of 72 (55-125) months, 184/193 patients (95%) could be reached. Causes of death during the follow-up were sudden (6 vs 14), non-sudden cardiac (8 vs 9), non cardiac (5 vs 9) and unknown (7 vs 6) in patients initially treated with amiodarone versus the control group respectively. The probability of death after 84 months was 30% in the amiodarone group and 45% in the control group, and was significantly lower in amiodarone treated patients with respect to all deaths (p = 0.024) as well as cardiac deaths (p = 0.027). This mortality reduction was only due to amiodarone treatment during the first year after the index infarction, whereas the survival curves did not differ significantly during the late follow-up. Thus, the risk of cardiac death is low after the first year after myocardial infarction and may not justify continued antiarrhythmic therapy in patients with initially complex asymptomatic ventricular arrhythmias.